217314-47-1

Basic information

• Product Name: METHYL 3-AMINO-5-METHOXYBENZOATE
• Synonyms: METHYL 3-AMINO-5-METHOXYBENZOATE;Benzoic acid,3-aMino-5-Methoxy-, Methyl ester
• CAS NO: 217314-47-1
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.19
• Mol File: 217314-47-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 335.219 °C at 760 mmHg
• Flash Point: 178.301 °C
• Appearance: /
• Density: 1.18 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.03±0.10(Predicted)
• CAS DataBase Reference: METHYL 3-AMINO-5-METHOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-AMINO-5-METHOXYBENZOATE(217314-47-1)
• EPA Substance Registry System: METHYL 3-AMINO-5-METHOXYBENZOATE(217314-47-1)

Safety Data

• Hazardous Substances Data: 217314-47-1(Hazardous Substances Data)

Usage

General Description

Methyl 3-amino-5-methoxybenzoate is a chemical compound with the molecular formula C9H11NO3. It is a derivative of benzoic acid and belongs to the class of organic compounds known as benzoates. METHYL 3-AMINO-5-METHOXYBENZOATE is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It has applications in the manufacturing of drugs and agrochemicals, and it is also used as a flavoring agent in the food industry. Methyl 3-amino-5-methoxybenzoate is a white to off-white crystalline powder with a slightly sweet odor. It is important to handle and store this compound in accordance with safety guidelines and regulations due to its potential health and environmental hazards.

Upstream product

• 217314-43-7 1-(3-methoxy-5-methoxycarbonylphenyl)-2,5-dimethyl-1H-pyrrole 
• 217314-45-9 methyl 3-amino-5-iodobenzoate 
• 78238-13-8 3-methoxy-5-nitrobenzoic acid methyl ester 
• 67-56-1 methanol 
• 74165-74-5 3-amino-5-methoxybenzoic acid 

Downstream Products

• 220965-92-4 3-<<<3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl>carbonyl>amino>-5-methoxybenzoic acid, methyl ester 
• 1003857-96-2 3-methoxy-5-pent-4-enylamino-benzoic acid methyl ester 
• 220965-93-5 3-<<<3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl>carbonyl>amino>-5-methoxybenzoic acid 
• 1375152-04-7 C₁₀H₁₃NO₅S 
• 1375152-12-7 C₁₅H₁₅NO₅S 
• 1375214-08-6 C₁₂H₁₆ClNO₅S 
• 717109-27-8 methyl 3-iodo-5-methoxybenzoate 
• 1346245-88-2 C₂₀H₁₇N₅O₂ 
• 1261566-52-2 (3-amino-5-methoxyphenyl)methanol 
• 1346245-87-1 C₂₀H₁₉N₅O₂ 
• 1346245-89-3 C₂₄H₂₈N₆O 
• 1017240-74-2 3-methoxy-5-(2-oxopyrrolidin-1-yl)benzoic acid 

Relevant articles and documents

New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

New drugs against visceral leishmaniasis with mechanisms of action differing from existing treatments and with adequate cost, stability, and properties are urgently needed. No antitubulin drug is currently in the clinic against Leishmania infantum, the causative agent of visceral leishmaniasis in the Mediterranean area. We have designed and synthesized a focused library of 350 compounds against the Leishmania tubulin based on the structure-activity relationship (SAR) and sequence differences between host and parasite. The compounds synthesized are accessible, stable, and appropriately soluble in water. We assayed the library against Leishmania promastigotes, axenic, and intracellular amastigotes and found 0, 8, and 16 active compounds, respectively, with a high success rate against intracellular amastigotes of over 10%, not including the cytotoxic compounds. Five compounds have a similar or better potency than the clinically used miltefosine. 14 compounds showed a host-dependent mechanism of action that might be advantageous as it may render them less susceptible to the development of drug resistance. The active compounds cluster in five chemical classes that provide structure-activity relationships for further hit improvement and facilitate series development. Molecular docking is consistent with the proposed mechanism of action, supported by the observed structure-activity relationships, and suggests a potential extension to other Leishmania species due to sequence similarities. A new family of diarylsulfonamides designed against the parasite tubulins is active against Leishmania infantum and represents a new class of potential drugs with favorable cost, stability, and aqueous solubility for the treatment of visceral leishmaniasis (VL). These results could be extended to other clinically relevant species of Leishmania spp.

KINASE INHIBITORS

There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members

MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.